Elixinol said it is buying the company for 3 million euros in cash ($3.6 million) plus 6 million euros in Elixinol shares ($7.2 million). The deal calls for Elixinol to pay up to 24 million euros ($29 million) if certain sales goals are met.
CannaCare is based in Hamburg, Germany, and makes CBD oils, sprays and skin-care products. The products are sold in 4,500 brick-and-mortar retail distribution points in Germany.
Elixinol CEO Oliver Horn said last summer that the global CBD company would focus on European CBD markets because the U.S. CBD market is “just so cluttered.”